Mevalonate Pathway Analysis Service

The mevalonate pathway is widely studied. This pathway is widely known being involved in cardiovascular diseases. Recently, a large number of experimental and clinical studies show that inhibition of non-sterol isoprenoids has important therapeutical implications. By synthesizing sterol isoprenoids, such as cholesterol, and non-sterol isoprenoids, this pathway plays an essential role in various cellular processes. Starting with acetyl-CoA, the mevalonate pathway ends with two five-carbon building blocks names as isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) used for making isoprenoids like cholesterol, coenzyme Q10, and all steroid hormones. This pathway, specifically HMG-CoA reductase in the mevalonate pathway, is a well-known target of a class of cholesterol lowering drugs—statins. Statins inhibits the activity of HMG-CoA reductase, and thereby inhibits the generation of cholesterol- one kind of isoprenoids.